SCA Pharmaceuticals Recalls Products Due to Potential Contamination

Article

The company is recalling several injectable products because of possible microbial contamination.

On Oct. 20, 2017, SCA Pharmaceuticals LLC announced it was voluntarily recalling several lots of injectable products to the hospital level because of a potential for microbial contamination.  The recalled products were distributed nationwide to hospitals.

The recalled products include Succinylcholine Chloride 20 mg/mL 10 mL syringe, Fentanyl 2 mcg/mL + Bupivacaine 0.125% in 250 mL 0.9% Sodium Chloride, Oxytocin 30 units added to 500 mL Lactated Ringers, and Calcium Gluconate 2 g added to 50 mL 0.9% Sodium Chloride. A complete list of recalled products can be found on FDA’s website.

While the company has not received any reports of adverse events as of the date of the recall, it cautions that using products that are intended to be sterile but may be contaminated may result in serious or even life-threatening infections. The company stated in a press release that patients should contact their healthcare provider if they experience any problems associated with the recalled products. Adverse events may be reported to FDA via their website

Source: FDA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content
© 2025 MJH Life Sciences

All rights reserved.